Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

8.3%

2 terminated out of 24 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

21%

5 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed with results

Key Signals

1 with results80% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (6)
P 1 (1)
P 2 (4)
P 3 (5)

Trial Status

Completed8
Recruiting6
Unknown4
Not Yet Recruiting3
Terminated2
Withdrawn1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT05798286Not ApplicableCompleted

Quantra® System With the QPlus® Cartridge in Double-lung Transplantation

NCT06066957Phase 2Recruiting

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT07588945Phase 3Not Yet RecruitingPrimary

daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

NCT06950788Recruiting

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

NCT07374874RecruitingPrimary

A Cohort Study on the Association Between the ANS Function and Acute GvHD

NCT06393660UnknownPrimary

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

NCT07157514Phase 2Not Yet Recruiting

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

NCT07013370Recruiting

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT05967130Phase 3Terminated

Treatment Chronic UTI Post Kidney Transplant

NCT03636412Not ApplicableCompletedPrimary

Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients

NCT06888479Phase 3Not Yet RecruitingPrimary

Optimal Timing of Hepatitis B Vaccination After Transplants

NCT05600855Phase 2CompletedPrimary

Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

NCT05599256Phase 2RecruitingPrimary

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

NCT03769441Phase 3Completed

Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation

NCT06208137Not ApplicableRecruitingPrimary

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

NCT03811873Not ApplicableCompleted

Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates

NCT05629923Completed

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

NCT04985409Not ApplicableCompleted

Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant

NCT05441436UnknownPrimary

Neuropsychological and Biopsychosocial Evolution During Pediatric Transplantation: Pre/Post-stages and at 6 Months

NCT04756622Phase 3Unknown

N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.

Scroll to load more

Research Network

Activity Timeline